Synovate Healthcare launches new Inflammatory Bowel Disease audit in the USA and Europe
29 June 2005
LONDON — SYNOVATE Healthcare, a global market research firm specialising in healthcare, has launched the Inflammatory Bowel Disease Monitor in both the US and Europe, expanding and strengthening their autoimmune portfolio. Synovate Healthcare has serviced the autoimmune market since 1997 with its unique expertise and knowledge gained through its' Global Multiple Sclerosis and Rheumatoid Arthritis monitors. Synovate Healthcare is confident it is the only company which can offer clients such a breadth of data, as well as depth.
Lucy Ireland, Manager of the Inflammatory Bowel Disease (IBD) Monitors commented "This launch represents another great step forward for us, we now have the opportunity to expand our expertise into two key new autoimmune disorders, allowing for in-depth analysis of these diseases as well as a helicopter view of overall brand performance across the Autoimmune area. In addition, offering our clients our usual outstanding level of service and therapy expertise will remain a key priority for us". We can also announce that the Autoimmune portfolio will further be expanded in the near future with the launch of a Global Psoriasis Monitor.
The Synovate Healthcare IBD Monitor is based on a representative panel of physicians who regularly report on their treatment of Crohn's Disease and Ulcerative Colitis patients across the US and Europe so that changes over time can be tracked. The Monitor collects physician perceptions of the market and the disease, as well as patient record information, so this can be compared, and validated, with the "actual patient" data. Doctor and patient segmentation models can also be developed using data from the monitors enabling tracking on how the disease is perceived, managed and treated over time.
Ulcerative Colitis and Crohn's Disease are becoming key areas of interest within the pharmaceutical industry, due to their severity and the increasing number of treatment options for the diseases. The market is likely to change noticeably in the next few years with over 20 products in the pipeline, and the Synovate Healthcare IBD monitor will prove a key tool to understanding the changes in this dynamic market.
For further details on Synovate Healthcare and the Global IBD Monitor visit www.synovate.com/healthcare or email us
Contact(s) for this press release
|
Claire Taylor
Marketing Executive |
|
|
Telephone: +44 208 246 6200 |
|
Synovate Healthcare is the global specialist healthcare market research arm of Synovate, dedicated to delivering marketing insights to the pharmaceutical and healthcare industries. Synovate Healthcare employs over 500 healthcare market research professionals across Europe, US, Canada, Asia Pacific and Japan and offers syndicated and custom research as well as global fieldwork capabilities.
More information on Synovate Healthcare can be found at www.synovate.com/healthcare.
About Synovate
Synovate generates insights to help clients drive competitive brand, product and customer experience strategies. Now part of Ipsos, with offices in over 80 countries, our approach combines best in class global research capabilities with personalised service, local knowledge and the flexibility to create teams and processes that meet clients' specific requirements. At Synovate, our clients sit at the top of our organisational chart, driving us to continually develop more innovative research solutions that predict actual business outcomes.
For more information on Synovate visit www.synovate.com.
About Aegis Group plc
Aegis Group plc is the holding company for Carat, its media strategy, planning and buying business, and Synovate, its market research business. These two operating groups provide clients with a range of services across media communications, marketing consultancy and market research. Listed on the London Stock Exchange, Aegis is capitalised at around £1.1 billion and operates in 64 countries.
More information on Aegis Group plc can be found at www.aegisplc.com.